BARC/PUB/2019/0936

  
 

Synthesis, radiolabeling, and evaluation of gastrin releasing peptide receptor antagonist 68Ga-HBED-CC-RM26
 
     
 
Author(s)

Satpati, D.; Vats, K.; Sharma, R.; Kameswaran, M.; Sarma, H. D.; Dash, A.
(RPhD;RB&HSD)

Source

Journal of Labelled Compounds and Radiopharmaceuticals, 2019. Vol. 62: pp. 843-849
ABSTRACT

The acyclic chelator HBED‐CC has attained huge clinical significance owing to high thermodynamic and kinetic stability of 68Ga‐HBED‐CC chelate. It provides an excellent platform for quick preparation of 68Ga‐based radiotracers in high yield. Thus, the present study aimed at conjugation of gastrin releasing peptide receptor (GRPr) antagonist, RM26, with HBED‐CC chelator for 68Ga‐labeling. In vitro and vivo behavior of the peptide tracer, 68Ga‐HBED‐CC‐PEG2‐RM26, was assessed and compared with 68Ga‐NODAGA‐PEG2‐RM26. The peptide tracers, 68Ga‐HBED‐CC‐PEG2‐RM26 and 68Ga‐NODAGA‐PEG2‐RM26, prepared either by wet chemistry or formulated using freeze‐dried kits exhibited excellent radiochemical yield and in vitro stability. The two peptide tracers cleared rapidly from the blood. Biodistribution studies in normal mice demonstrated slightly higher or comparable uptake of 68Ga‐HBED‐CC‐PEG2‐RM26 in GRPr‐expressing organs pancreas, stomach, and intestine. The preliminary studies suggest high potential of 68Ga‐HBEDCC‐PEG2‐RM26 for further investigation as a GRPr imaging agent and thewide scope of HBED‐CC chelator in development of 68Ga‐based peptide tracers.
 
 
SIRD Digital E-Sangrahay